FlavoTear represents a clinical shift in treating Dry Eye Disease (DED) by moving beyond symptomatic relief to a "disease-modifying" approach. Utilizing Baicalein, a plant-derived bioactive flavonoid, the treatment targets the "vicious cycle" of the disease—specifically the chronic inflammation, oxidative stress, and cell death that lead to tear film instability.
Dry Eye Disease is featured with the vicious cycle, including inflammation and oxidative stress. The conventional treatments could not fully tackle the disease with the following limitations:
Baicalein, a bioactive plant-derived flavonoid, offers a multifunctional therapeutic solution for DED through its potent anti-inflammatory, anti-oxidative, and anti-apoptotic properties that disrupt the disease's vicious cycle. In hyperosmolar human corneal epithelial cell models, baicalein significantly reduced elevated cytokine expression, enhanced wound healing, and improved cell viability. It also suppressed mitochondrial reactive oxygen species and malondialdehyde levels, indicating protection against oxidative damage and mitochondrial dysfunction. This allows Baicalein to treat the root cause of dry eye — the "vicious cycle" of inflammation and oxidative stress 一rather than merely masking the symptoms.
Pharmaceutical Development
Prof. Chi Wai DO, Principal Investigator, CEVR
Pro. Emmanuel HO, Principal Investigator, CEVR
Mr. Roy CHUNG, Research Associate, CEVR
Mr. Roy CHUNG, Research Associate, CEVR
No related ventures available in this category.